title: Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma.
abstract: The aim of the present study was to evaluate the efficacy and toxicity of stereotactic body radiation therapy (SBRT) for low- to intermediate-risk prostate adenocarcinoma. Thirty-nine patients were retrospectively reviewed. The SBRT was delivered using the CyberKnife with the fiducial tracking method combined with In-tempo imaging. The gross target volume, which included the prostate only, was delineated on the fused CT/MRI scans. The prescription dose was delivered every other day as 5 fractions of 7.5 Gy. Venous blood was obtained before and after SBRT to assess the prostate-specific antigen (PSA) level. Toxicity was evaluated using the CTCAE, v4.03. The median follow-up time was 30.0 months. The median initial PSA level was 7.7 ng/mL. PSA levels decreased in all patients treated with SBRT, and after 5 months, the median PSA was less than 2 ng/mL. The rate of overall 3-yr actuarial biochemical failure free survival was 93.9%. Acute side effects were generally comparable with those of previous studies. The PSA change and toxicity after SBRT for low- to intermediate-risk prostate adenocarcinoma indicates favorable biochemical responses and tolerable levels of toxicity. Additionally short course treatment may produce cost benefit and convenience to patients.
authors.affiliation: Department of Radiation Oncology, Gyeongsang National University School of Medicine, Jinju, Korea. ; Institute of Health Science, Gyeongsang National University, Jinju, Korea.
authors.forename: Bae-Kwon
authors.identifier: 0000-0001-8015-6061
authors.initials: BK
authors.lastname: Jeong
authors.affiliation: Department of Radiation Oncology, Gyeongsang National University School of Medicine, Jinju, Korea. ; Institute of Health Science, Gyeongsang National University, Jinju, Korea.
authors.forename: Hojin
authors.identifier: 0000-0003-0867-3616
authors.initials: H
authors.lastname: Jeong
authors.affiliation: Department of Radiation Oncology, Gyeongsang National University School of Medicine, Jinju, Korea.
authors.forename: In Bong
authors.identifier: 0000-0001-6007-8756
authors.initials: IB
authors.lastname: Ha
authors.affiliation: Department of Radiation Oncology, Gyeongsang National University School of Medicine, Jinju, Korea.
authors.forename: Hoon Sik
authors.identifier: 0000-0003-0998-0685
authors.initials: HS
authors.lastname: Choi
authors.affiliation: Department of Urology, Gyeongsang National University School of Medicine, Jinju, Korea.
authors.forename: Sung Chul
authors.identifier: 0000-0001-5403-3623
authors.initials: SC
authors.lastname: Kam
authors.affiliation: Department of Urology, Gyeongsang National University School of Medicine, Jinju, Korea. ; Institute of Health Science, Gyeongsang National University, Jinju, Korea.
authors.forename: Jeong Seok
authors.identifier: 0000-0003-3821-5237
authors.initials: JS
authors.lastname: Hwa
authors.affiliation: Department of Urology, Gyeongsang National University School of Medicine, Jinju, Korea. ; Institute of Health Science, Gyeongsang National University, Jinju, Korea.
authors.forename: Jae Seog
authors.identifier: 0000-0002-8820-4117
authors.initials: JS
authors.lastname: Hyun
authors.affiliation: Department of Urology, Gyeongsang National University School of Medicine, Jinju, Korea. ; Institute of Health Science, Gyeongsang National University, Jinju, Korea.
authors.forename: Ky Hyun
authors.identifier: 0000-0003-2854-8708
authors.initials: KH
authors.lastname: Chung
authors.affiliation: Institute of Health Science, Gyeongsang National University, Jinju, Korea.
authors.forename: See Min
authors.identifier: 0000-0002-6599-2640
authors.initials: SM
authors.lastname: Choi
authors.affiliation: Department of Radiation Oncology, Gyeongsang National University School of Medicine, Jinju, Korea. ; Institute of Health Science, Gyeongsang National University, Jinju, Korea.
authors.forename: Ki Mun
authors.identifier: 0000-0002-6123-9635
authors.initials: KM
authors.lastname: Kang
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000601:surgery*; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000601:surgery*; D016634:Radiosurgery / Q000379:methods*; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D061089:Radiotherapy, Image-Guided / Q000379:methods*; D018570:Risk Assessment; D016896:Treatment Outcome
keywords: Cyberknife Radiosurgery; Prostate Neoplasms; Prostate-Specific Antigen; Stereotactic Body Radiation Therapy